直 Japanese PDF Font
  • Our Professionals
  • Our Work
  • Our Insights
  • Offices
  • Firm
  • Careers
Finnegan
  • Articles & Books
    • Ad Law Buzz Blog
    • At the PTAB Blog
    • European IP Blog
    • Federal Circuit IP Blog
    • INCONTESTABLE® Blog
    • Prosecution First Blog
  • Events & Webinars
  • IP Updates
  • Podcasts
    • AI + Finnegan
    • AI + Copyright
    • AI + Patent
    • AI + Privacy
    • AI + Trade Secrets
    • AI + Trademark
  • Unified Patent Court (UPC) Hub

Federal Circuit IP Blog

En Banc Court to Decide Two Important Exhaustion Issues

June 05, 2015

Authored and Edited by Kevin D. Rodkey; Kathleen A. Daley; Elizabeth D. Ferrill

In a rare move, the Federal Circuit sua sponte ordered hearing en banc and additional briefing on questions related to patent exhaustion in Lexmark International, Inc. v. Impression Products, Inc., Nos. 14-1617, -1619 (Fed. Cir. Apr. 14, 2015).

The doctrine of “patent exhaustion” provides that the first authorized sale of a patented item “exhausts” a patentee’s right to control the post-sale activities of that item. This doctrine is based on the theory that a lawful buyer should be free to use the patented item without restriction from the patentee. Although the doctrine has a lengthy history, two recent Supreme Court decisions have highlighted several important issues. The Federal Circuit is now poised to resolve two of these issues en banc.

The first issue is whether the Federal Circuit should overrule Jazz Photo Corp. v. International Trade Commission, 264 F.3d 1094 (Fed. Cir. 2001), which held that foreign sales of a patented item do not exhaust patent rights in the United States (so-called “international exhaustion”). Impression asks the Court to overrule Jazz Photo based on the Supreme Court’s decision in Kirtsaeng v. John Wiley & Sons, Inc., 133 S. Ct. 1351 (2012), which held that copyrighted, not patented, material sold abroad was exhausted under the Copyright Act’s first-sale provisions. The issue of international exhaustion has implications in today’s global economy where patented products may be sold abroad and imported to the United States.

The second issue is whether the Federal Circuit should overrule Mallinckrodt, Inc. v. Medipart, Inc., 976 F.2d 700 (Fed. Cir. 1992), which held that the sale of a patented article made under a lawful restriction within the scope of the patent grant does not exhaust the patentee’s rights in the article. Mallinckrodt concerned the scope of a patentee’s right to condition authorized sales, holding that some restrictions, such as “single use only” restrictions, could preclude a finding of exhaustion. The district court found that the Supreme Court’s decision in Quanta Computer, Inc. v. LG Electronics, Inc., 553 U.S. 617 (2008), overruled Mallinckrodt, and Lexmark asks the Court to reverse the decision below and uphold both Mallinckrodt and Lexmark’s current post-sale provisions.

At issue is the enforceability of Lexmark’s cartridge “prebate” program in which an end user can either buy a full-price printer ink cartridge without any restrictions on its use or the user can buy a discounted cartridge on the condition that the cartridge is returned to Lexmark for disposal or refurbishment. Although neither party appears to challenge that the program created a valid contract between Lexmark and the sellers and end users of Lexmark’s products, the parties dispute whether Lexmark’s patent rights are exhausted or whether Lexmark can hold Impression liable for patent infringement after Impression bought, refurbished, and resold Lexmark’s patented cartridges.

The Federal Circuit has ordered briefing and an en banc hearing to resolve these two questions. While both of these questions are individually noteworthy, the en banc order makes this a case to watch.

Tags

defense, post-sale restrictions

Related Practices

Diligence, Licensing, and Opinions

Licensing, Pooling, and Other Transactions

Contacts

Kevin D. Rodkey
Partner
Atlanta, GA
+1 404 653 6484
Email
Kathleen A. Daley
Partner
Washington, DC
+1 202 408 4098
Email
Elizabeth D. Ferrill
Partner
Washington, DC
+1 202 408 4445
Email

Copyright © 2015 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP. 


DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.

Related Insights

Charitable

Bridges From School to Work Gala 2026

June 22, 2026

Washington, DC

Charitable

Banding Together 2026

June 18, 2026

Washington, DC

Articles

Article_D.-Mass-Patent-Litigation-Update-October-2024

D. Mass. Patent Litigation Update: April 2026

June 1, 2026

At the PTAB Blog

Consistency Is Key – USPTO Issues Three New Informative Decisions

May 29, 2026

At the PTAB Blog

Discretion All the Way Down: USPTO Uses a Discretionary IPR Denial to Justify a    
§ 325(d) EPR Denial

May 28, 2026

At the PTAB Blog

IPR and PGR Statistics for Final Written Decisions Issued in March and April 2026

May 26, 2026

At the PTAB Blog

Claim Disclaimer Derails Instituted IPR in Freightcar America

May 26, 2026

At the PTAB Blog

Before the Holding, the Message: Director Squires Uses Magnolia Medical to Outline PTAB Discretionary Denial Policy Changes

May 20, 2026

Conference

19th Annual Forum on Pharma & Biotech Patent Litigation in Europe

May 19-20, 2026

Amsterdam

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.

  • Privacy
  • Disclaimer
  • Legal Notices
  • Fraud Alert
  • EEO Statement
  • Cookies
  • Contact Us

© 2026 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP